Stock Events

Dexcom 

$74.65
332
+$2.29+3.16% Friday 20:00

Statistics

Day High
74.73
Day Low
72.51
52W High
142
52W Low
62.34
Volume
3,122,863
Avg. Volume
9,517,941
Mkt Cap
29.91B
P/E Ratio
47.25
Dividend Yield
-
Dividend
-

Upcoming

Earnings

24OctConfirmed
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Q2 2024
Next
0.14
0.26
0.38
0.5
Expected EPS
0.435085
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow DXCM. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Abbott Laboratories
ABT
Mkt Cap189.14B
Abbott Laboratories competes with Dexcom in the continuous glucose monitoring (CGM) market, particularly with their FreeStyle Libre system.
Medtronic
MDT
Mkt Cap105.2B
Medtronic is a direct competitor in the CGM and diabetes management market, offering products like the Guardian Connect system.
Tandem Diabetes Care
TNDM
Mkt Cap2.45B
Tandem Diabetes Care partners with Dexcom for CGM integration but also competes in providing comprehensive diabetes management solutions.
Insulet
PODD
Mkt Cap12.76B
Insulet Corporation's Omnipod system is a competitor in the broader diabetes management space, offering an alternative to traditional insulin delivery and monitoring systems.
Senseonics
SENS
Mkt Cap202.18M
Senseonics Holdings offers the Eversense CGM system, providing long-term implantable glucose monitoring, a direct competitor to Dexcom's wearable CGM products.
Novo Nordisk
NVO
Mkt Cap452.48B
Novo Nordisk competes indirectly through their extensive range of diabetes care products, including insulin and non-insulin treatments, which are part of integrated diabetes management.
Sanofi
SNY
Mkt Cap132.87B
Sanofi competes in the diabetes market with its insulin and glucose monitoring solutions, offering an alternative to Dexcom's CGM systems.
Mckesson
MCK
Mkt Cap70.17B
McKesson Corporation, through its distribution of diabetes care products including CGMs, competes in the broader market for diabetes management solutions.
Cardinal Health
CAH
Mkt Cap24.52B
Cardinal Health is involved in the distribution of various healthcare products, including diabetes care supplies, competing in the broader market for diabetes management.

Analyst Ratings

108$Average Price Target
The highest estimate is $161.
From 15 ratings within the last 6 months. This is not an investment recommendation.
Buy
67%
Hold
33%
Sell
0%

About

Health Technology
Medical Specialties
Manufacturing
Surgical and Medical Instrument Manufacturing
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
Show more...
CEO
Kevin Sayer
Employees
9500
Country
US
ISIN
US2521311074
WKN
000A0D9T1

Listings